The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 21, 2006
Filed:
Aug. 07, 2000
Werner Breitenstein, Basel, CH;
Kenji Hayakawa, Takarazuka, JP;
Genji Iwasaki, Tsukuba, JP;
Takanori Kanazawa, Tsukuba, JP;
Tatsuhiko Kasaoka, Tsukuba, JP;
Shinichi Koizumi, Inashiki-gun, JP;
Shinichiro Matsunaga, Tsukuba, JP;
Motowo Nakajima, Ashiya, JP;
Junichi Sakaki, Kawasaki, JP;
Werner Breitenstein, Basel, CH;
Kenji Hayakawa, Takarazuka, JP;
Genji Iwasaki, Tsukuba, JP;
Takanori Kanazawa, Tsukuba, JP;
Tatsuhiko Kasaoka, Tsukuba, JP;
Shinichi Koizumi, Inashiki-gun, JP;
Shinichiro Matsunaga, Tsukuba, JP;
Motowo Nakajima, Ashiya, JP;
Junichi Sakaki, Kawasaki, JP;
Novartis AG, Basel, CH;
Abstract
α-Amino hydroxamic acid derivative of formula (I), in which R is C–C-alkyl, which is mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C–C-cycloalkyl or unsubstituted or substituted C–C-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; or C–C-alkenyl or C–C-alkynyl, which in each case is unsubstituted or mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C–C-cycloalkyl or unsubstituted or substituted C–C-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; and the other symbols are as defined in claim, are described. These compounds are MMP and in particular MMP2 inhibitors and can be used for treatment of MMP dependent diseases, in particular inflammation conditions, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or invasi n) and pulmonary disorders (e.g. emphysema, COPD).